BR Biopharma (BRBI) Stock Price, News & Analysis

Company Overview

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.

Key Stats

• Today's Range: $10.95 to $11.09
• 50-Day Range: $9.13 to $12.13
• 52-Week Range: $9.09 to $67.01
• Volume: 347 shs
• Average Volume: 851 shs
• Market Capitalization: $131.00 million
• P/E Ratio: 138.65
• Dividend Yield: 3.79%
• Price Target: N/A
• Consensus Rating: Sell

BR Biopharma Stock Analysis - MarketRank™

BR Biopharma scored higher than 11% of companies evaluated by MarketBeat, and ranked 777th out of 836 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

BR Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

BR Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BR Biopharma is 138.65, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.80.

Price to Earnings Ratio vs. Sector

The P/E ratio of BR Biopharma is 138.65, which means that it is trading at a more expensive P/E ratio than the Finance sector average P/E ratio of about 25.79.

Price to Book Value per Share Ratio

BR Biopharma has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.03% of the float of BR Biopharma has been sold short.

Short Interest Ratio / Days to Cover

BR Biopharma has a short interest ratio ("days to cover") of 4.77.

Change versus previous month

Short interest in BR Biopharma has recently increased by 50.89%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

BR Biopharma is a leading dividend payer. It pays a dividend yield of 3.83%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

BR Biopharma does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of BR Biopharma is 525.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BR Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

29.35% of the stock of BR Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

BR Biopharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 6/30/2026
• Record date for 9/4 Dividend: 8/17/2026
• Ex-Dividend for 9/4 Dividend: 8/17/2026
• Dividend Payable: 9/04/2026
• Today: 9/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Finance
• Industry: Capital Markets
• Sub-Industry: Investment Banking & Brokerage
• Current Symbol: NASDAQ:BRBI
• CIK: 2058601
• Web: www.ri.brpartners.com.br
• Phone: 55-11-3704-1000
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 138.65
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.87
• Quick Ratio: 0.87

Sales & Book Value

• Annual Sales: $2.23 billion
• Price / Sales: 0.06
• Cash Flow: $2.87 per share
• Price / Cash Flow: 3.87
• Book Value: $11.88 per share
• Price / Book: 0.93

Miscellaneous

• Outstanding Shares: 11,810,000
• Free Float: 8,344,000
• Market Cap: $131.00 million
• Optionable: N/A
• Beta: N/A